Meningococcal vaccines market set to approach $1.8 billion by 2025; Report

The meningococcal vaccines market is expected to grow from around $1.1 billion in 2015 to $1.8 billion by 2025 across the eight major markets (8MM) of the USA, France, Germany, Italy, Spain, the UK, Japan, and Brazil, representing a compound annual growth rate (CAGR) of 5.4%.

According to research and consulting firm GlobalData’s latest report, this substantial growth will mainly be driven by adjustments in national immunization schedules, as governments implement more inclusive vaccination schedules to prevent invasive meningococcal disease. It will also be propelled by the anticipated launch of a first-in-class vaccine covering all serogroups currently prevalent in the 8MM by combining two different meningococcal vaccines, thereby decreasing the dosage burden involved in vaccinations.

Mirco Junker, GlobalData’s analyst covering infectious diseases, says: “Although the meningococcal vaccine market in the 8MM is highly mature, and the continuous decline in incidence rates of meningococcal disease across most of these countries will act as a barrier to launching new products, there will be several opportunities for a current or future player to distinguish itself from the competition.”